Replies to post #152486 on Biotech Values

[mcbio]

True re: the historical data, but they data they use seems to be matched up well with what you would expect.

Too bad the Phase 3 is going to take forever.

I still say the key near-term for CLDX is the 011 update next month at the SABCS. I am holding in full through that event. CLDX also just said at Lazard they intend to expand testing of 011 into other indications where they see high GPNMB. Hopefully this bodes well for the update in breast cancer at the SABCS but, as always, no guarantees.